Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 4,672 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions: Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids; Drug · Procedure
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Chronic Rhinosinusitis, Sinusitis
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 4,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Sheffield, Alabama • Northridge, California • Cutler Bay, Florida + 9 more

Conditions: Anxiety Disorder, Head and Neck Cancer, Lung Cancer
Interventions: Medical chart review, Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory, management of therapy complications, Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID, Functional Assessment of Cancer Therapy-General (FACT-G); Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Lung Cancer
Interventions: computed tomography, positron emission tomography, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Cancer
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Milene Saavedra; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 99 Years
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 47
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more

Conditions: Hypertension, Pulmonary
Interventions: Aspirin, clopidogrel; Drug
Lead sponsor: Kawut, Steven, MD; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Pulmonary Fibrosis
Interventions: pomalidomide (CC-4047; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sleep Disordered Breathing, Able Bodied
Interventions: Trazodone + positive airway pressure (PAP) therapy, Oxygen + positive airway pressure (PAP) therapy; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: COPD
Interventions: PT010, PT009, Symbicort Turbohaler; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: 20 mg laninamivir octanoate, Placebo, 40 mg laninamivir octanoate; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more

Conditions: Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cytology specimen collection procedure, therapeutic procedure, targeted therapy, laboratory biomarker analysis; Other · Procedure · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Malignant Uterine Neoplasm, Vulvar Cancer, Invasive Breast Cancer, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vulvar Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vulva Squamous Cell Carcinoma
Interventions: Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Non-Small-Cell Lung Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: COVID-19
Interventions: Dapsone 85 mg PO BID, Placebo 85 mg PO BID; Drug
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 40 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: No Intervention; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Health Behavior, Health Care Utilization
Interventions: Phase II Promotores de Salud, Phase I Promotores de Salud Outreach; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 3 Years and older
Enrollment: 1,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Eugene, Oregon

Search by objective public record fields.

A Study With Imlifidase in Anti-GBM Disease

Medical Therapy Versus Sinus Surgery for Chronic Rhinosinusitis: A Prospective, Multi-institutional Study

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck Cancer

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

Phase II Trial of Continuation Therapy in Advanced NSCLC

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II